In a joint announcement, Merck and Moderna said their personalized mRNA cancer vaccine, used alongside Merck’s immunotherapy Keytruda, achieved significant success in a large Phase 3 trial involving high‑risk melanoma patients whose tumors had been surgically removed.
The trial demonstrated a substantial reduction in the risk of cancer returning or spreading. Specifically, the Phase 2b portion of the study reported a 49% decrease in melanoma recurrence and a 59% drop in metastasis to distant organs compared with standard treatment alone.
Researchers described the approach as “individualized neoantigen therapy.” By sequencing the genetic material of each patient’s tumor, the vaccine is tailored to target unique mutational fingerprints, prompting the immune system to recognize and attack residual cancer cells after surgery.
Dr. Ahmad Tarhini, an oncologist at the H. Lee Moffitt Cancer Center & Research Institute, told ABC News that the data are compelling enough to anticipate FDA approval, with a potential patient rollout as early as 2027. He emphasized the safety profile, noting that most side effects were mild—fatigue, soreness at the injection site, and occasional chills.
While the Food and Drug Administration has not yet granted approval for this specific vaccine, it has previously cleared other cancer vaccines. The agency will review the full data set once the companies submit a formal application.
Implications for melanoma treatment
Melanoma remains the deadliest form of skin cancer, with the American Cancer Society projecting roughly 112,000 new cases in 2026. Current standard care often includes surgery followed by immunotherapy such as Keytruda, but recurrence rates remain a concern. The addition of a personalized mRNA vaccine could shift the treatment paradigm, offering a more durable defense against disease return.
Beyond melanoma, Moderna and Merck indicated that mRNA technology is being explored in trials for other cancers, including bladder, kidney, lung, stomach, and pancreatic cancers. Success in melanoma may accelerate development and regulatory pathways for these additional indications.
Next steps
Merck and Moderna plan to present the full trial data at an upcoming international medical conference, where they hope to engage regulators and clinicians about filing for approval. If the FDA grants clearance, the regimen could become the first approved combination of a personalized mRNA vaccine with an existing checkpoint inhibitor for any cancer.
Patients, families, and healthcare providers are watching closely, as the potential to extend survival and reduce the burden of metastatic disease aligns with broader goals of improving outcomes while maintaining quality of life.
Original reporting: Brookhaven News – ABC7 New York — read the source article.
